Glenn Crater

2.2k total citations
80 papers, 1.7k citations indexed

About

Glenn Crater is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Glenn Crater has authored 80 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pulmonary and Respiratory Medicine, 44 papers in Physiology and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Glenn Crater's work include Chronic Obstructive Pulmonary Disease (COPD) Research (53 papers), Asthma and respiratory diseases (41 papers) and Inhalation and Respiratory Drug Delivery (23 papers). Glenn Crater is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (53 papers), Asthma and respiratory diseases (41 papers) and Inhalation and Respiratory Drug Delivery (23 papers). Glenn Crater collaborates with scholars based in United States, United Kingdom and Canada. Glenn Crater's co-authors include Rashmi Mehta, Amanda Emmett, Alison Church, Maggie Tabberer, G. Holzwarth, Dianne M. O’Dell, Christopher Kalberg, Antonio Anzueto, James F. Donohue and Stephanie Harris and has published in prestigious journals such as Nucleic Acids Research, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Glenn Crater

74 papers receiving 1.6k citations

Peers

Countries citing papers authored by Glenn Crater

Since Specialization

Citations

This map shows the geographic impact of Glenn Crater's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glenn Crater with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glenn Crater more than expected).

Fields of papers citing papers by Glenn Crater

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glenn Crater. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glenn Crater. The network helps show where Glenn Crater may publish in the future.

Co-authorship network of co-authors of Glenn Crater

This figure shows the co-authorship network connecting the top 25 collaborators of Glenn Crater. A scholar is included among the top collaborators of Glenn Crater based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glenn Crater. Glenn Crater is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial 2025 ·The Lancet Diabetes & Endocrinology ·Filip K. Knop, George Kunos, Dror Dicker, Jean‐Sébastien Paquette, Louis J. Aronne, (unknown), Thomas Holst‐Hansen, Karine Lalonde, Jisoo Lee, Glenn Crater	1
2	Effects of CB1R inverse agonist, INV ‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study 2023 ·Diabetes Obesity and Metabolism ·Glenn Crater, Karine Lalonde, François Ravenelle, Michael Harvey, Jean‐Pierre Després	23
3	Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Patricia Passilly‐Degrace, (unknown), (unknown), Julia Leemput, (unknown), Laurent Demizieux, Bruno Vergès, Pascal Degrace, Glenn Crater, Tony Jourdan	11
4	Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease 2022 ·Therapeutic Advances in Respiratory Disease ·Glenn Crater, (unknown), Jonathan K. Ward, Jan De Backer	2
5	Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease 2019 ·Respiratory Medicine ·James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, (unknown), Chris N. Barnes, Edmund J. Moran, Glenn Crater	26
6	Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate 2019 ·Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation ·Donald A. Mahler, Jill Ohar, (unknown), Edmund J. Moran, Srikanth Pendyala, Glenn Crater	29
7	Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study 2014 ·International Journal of COPD ·James F. Donohue, (unknown), Glenn Crater, Kathleen Rickard	53
8	Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD 2014 ·CHEST Journal ·Bartolomé R. Celli, Glenn Crater, Sally Kilbride, Rashmi Mehta, Maggie Tabberer, Chris Kalberg, Alison Church	133
9	Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials 2014 ·The Lancet Respiratory Medicine ·Marc Decramer, Antonio Anzueto, Edward Kerwin, (unknown), Nathalie Richard, Glenn Crater, Maggie Tabberer, Stephanie Harris, Alison Church	193
10	Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: Two randomised clinical trials 2013 ·European Respiratory Journal ·François Maltais, Sally J Singh, Alison Donald, Alison Church, Glenn Crater, (unknown), John Riley	6
11	Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD 2013 ·European Respiratory Journal ·Marc Decramer, Antonio Anzueto, Edward Kerwin, Nathalie Richard, Glenn Crater, Maggie Tabberer, Stephanie Harris, Alison Church	1
12	A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD 2012 ·Respiratory Medicine ·James F. Donohue, Antonio Anzueto, Jean Brooks, Rashmi Mehta, Christopher Kalberg, Glenn Crater	60
13	Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients 2012 ·Respiratory Physiology & Neurobiology ·Marc Decramer, François Maltais, Gregory Feldman, Jean Brooks, Stephanie Harris, Rashmi Mehta, Glenn Crater	48
14	Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy 2012 ·Respiratory Medicine ·Anand A. Dalal, Manan Shah, Anna O. D’Souza, Glenn Crater	14
15	Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD) 2011 ·European Respiratory Journal ·Dennis Kelleher, Andrew Preece, Rashmi Mehta, Alison Donald, Kelly Hardes, Anthony Cahn, Glenn Crater	4
16	Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD 2011 ·European Respiratory Journal ·Rashmi Mehta, Amy Newlands, Dennis Kelleher, Andrew Preece, Anthony Cahn, Glenn Crater	7
17	Triple Therapy of Fluticasone Propionate/Salmeterol Combination 250/50 mcg and Tiotropium Improves Lung Function Compared to Tiotropium Monotherapy 2010 ·CHEST Journal ·Nicola A. Hanania, Dennis E. Niewoehner, Glenn Crater, Amanda Emmett, (unknown), Michael J. Cicale	2
18	Disease severity and symptoms among patients receiving monotherapy for COPD 2010 ·Primary Care Respiratory Journal ·Mark T. Dransfield, William C. Bailey, Glenn Crater, Amanda Emmett, Dianne M. O’Dell, Barbara P. Yawn	48
19	Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol 2009 ·The Journal of Rheumatology ·David B. Badesch, Michael D. McGoon, (unknown), Victor F. Tapson, Lewis J. Rubin, Fredrick M. Wigley, Kenneth M. Kral, Ibrahim Raphiou, Glenn Crater	59
20	Mobility surfaces for field‐inversion gel electrophoresis of linear DNA 1989 ·Electrophoresis ·Glenn Crater, (unknown), G. Holzwarth	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact